MedPath

Establishment of the method for predicting clinical effect of tocilizumab based on its serum concentration in rheumatoid arthritis patients

Not Applicable
Recruiting
Conditions
rheumatoid arthritis
Registration Number
JPRN-UMIN000041153
Lead Sponsor
Department of Hospital pharmacy Hamamatsu University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients discontinuing tocilizumab. 2. Patients who are judged by physicians as inappropriate for study enrollment

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum tocilizumab concentration before dosing by intravenous or subcutaneous injection
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath